Skip to main content

Precision Therapies
Engineered for Change.

00_Home.
Revolutionising Cancer Treatment.

_Platform.

Odysseus® Platform.

Through our proprietary gene therapy platform, Odysseus®, we’re uniquely positioned to develop precision cancer treatments that selectively target diseased cell states and behaviour, combining payloads that reveal cancer to the body’s immune system and kill tumour cells.

_Approach.

Precision Therapies.

Our approach allows for selective treatment of cancer cells without toxicity to healthy tissue.

Like a Trojan horse, our therapy hides within the tumour, awakening the immune system and offering long-term protection against recurrence.

This potentially offers a paradigm shift from chronic disease management to one-time curative therapies.

01_About

_Science.

Synthetic Super-Enhancers (SSEs).

We’re revolutionising cancer treatment through our innovative Synthetic Super-Enhancers (SSEs) technology.

These SSEs are engineered DNA elements that are only activated in diseased cell states. SSEs act as docking stations for transcription factors uniquely expressed in aggressive cancer or diseased cells, allowing for highly selective and potent gene control.

Discover Our Breakthrough Technology.
02_Science

_Technologies.

Why Trogenix?

While immunotherapy has shown remarkable success in some cancers, significant challenges remain. Traditional therapies often fall short due to tumour heterogeneity and the immunosuppressive tumour environment.

At Trogenix, we’ve overcome these challenges by uniting cuttingedge technologies.

SSEs

Our SSEs target the genetic and phenotypic identity common to all cancer cells.

Precision

Our precision delivery system ensures potent localised treatment.

Approach

Our three-pronged approach combines controlled cell killing, immune modulation, and long-term protection.

Beyond Cancer.

The precision and versatility of our SSE technology extends beyond cancer treatment.

We’re building a future where aggressive cancers become curable diseases, and our innovative technology platform helps address multiple areas of unmet medical need.

03_Pipeline

Our platform has potential applications in

  • Solid Tumours.

  • Regenerative Medicine.

_News & Events.

Latest News.

Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.
November 18, 2024

Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
04_New & Events